Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
Geron (Nasdaq: GERN) will release its first quarter 2026 financial results and business highlights before the market opens on May 6, 2026.
Rhea-AI Summary
Geron (Nasdaq: GERN) will release its first quarter 2026 financial results and business highlights before the market opens on May 6, 2026.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time, with live and archived audio available from the Investors and Media section of its website at www.geron.com.
Positive
- None.
Negative
- None.
Details
News Market Reaction – GERN
In the Apr 22 session, GERN gained 3.33%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Total revenue
- $47.3M
- Q3 2025 results
- Net product revenue
- $47.2M
- Q3 2025 RYTELO sales
- Net loss
- $18.4M
- Q3 2025
- EPS
- -$0.03
- Q3 2025 basic and diluted loss per share
- Cash & securities
- $421.5M
- As of Sept 30, 2025
- Inventory
- $95.4M
- RYTELO supply, Sept 30, 2025
- Noncurrent debt
- $119.3M
- As of Sept 30, 2025
- Stockholders’ equity
- $248.7M
- As of Sept 30, 2025
Previous Earnings date Reports
-
Set date and time for Q4 and full-year 2025 earnings call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.